Navigation Links
Different anticoagulant regimens yield equal results

NEW YORK, NY DECEMBER 4, 2007 Patients with acute coronary syndromes (ACS) receiving early invasive treatment including angiography and percutaneous coronary intervention (PCI) have comparable results at 1 year in terms of mortality and ischemic outcomes no matter which of three different anticoagulant regimens they are on, according to a study in the December 5 issue of the Journal of the American Medical Association.

Researchers led by Gregg W. Stone, MD, Chairman of the Cardiovascular Research Foundation in New York and Professor of Medicine and Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy, Columbia University Medical Center, looked at over 13,000 patients with ACS (unstable angina or less severe heart attacks known as non-ST-elevation myocardial infarctions) who were given either heparin plus glycoprotein (GP) IIb/IIIa inhibitors (4,603 patients), the thrombin (blood-clotting enzyme) inhibitor bivalirudin by itself (4,612 patients), or bivalirudin plus GB IIb/IIIa inhibitors (4,604 patients).

Anticoagulant drug regimens are normally given in patients undergoing PCI to reduce the bleeding and ischemic complications that can result from these procedures. In earlier research, the same group of investigators showed that patients with ACS who received an early invasive management strategy who received bivalirudin alone experienced similar rates of ischemic complications but significantly reduced rates of major bleeding at 30 days compared with similar patients receiving bivalirudin plus GP IIb/IIIa inhibitors. As a result, less blood transfusions were required in this group of patients, and hospital costs were reduced. However, the long-term effect of bivalirudin monotherapy on composite ischemia and death are unknown.

In the short term, the optimal pharmacological regimen to support the invasive approach in ACS would ideally suppress adverse ischemic and thrombotic events while minimizing iatrogenic [induced by treatment] bleeding, Dr. Stone said.

Results from the recent study, called the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial, showed that compared with the control group of heparin plus GP IIb/IIIa inhibitors in which the 1-year estimated rate of composite ischemia was 15.4 percent, composite ischemia occurred in 16.0 percent of patients assigned to bivalirudin plus GP IIb/IIIa inhibitors and in 16.2 percent of patients assigned to bivalirudin alone. Death at 1 year occurred in an estimated 3.9 percent of patients assigned to heparin plus GP IIb/IIIa inhibitors, 3.9 percent assigned to bivalirudin plus GP IIb/IIIa inhibitors, and 3.8 percent assigned to bivalirudin monotherapy. Between 30 days and 1 year, a trend was present for fewer deaths in the patients assigned to bivalirudin monotherapy compared to heparin plus IIb/IIIa inhibitors or bivalirudin plus IIb/IIIa inhibitors (96 vs. 114 vs. 105 deaths respectively).

At 1 year, there were no statistically significant differences in the rates of composite ischemia or mortality among patients with moderate- and high-risk ACS undergoing invasive treatment with the three anticoagulant regimens, Dr. Stone said. Thus, bivalirudin alone, which decreases bleeding and transfusions, as well as hospital costs, as well as simplifies and streamlines care compared to heparin plus IIb/IIIa inhibitors, should be favored in most patients with ACS undergoing early invasive treatment.


Contact: Claire Laporte
Cardiovascular Research Foundation

Related medicine news :

1. Brain cells work differently than previously thought
2. Different method of evaluating the urinary tract system reduces radiation dose
3. Different HIV rates among gay men and straight people not fully explained by sexual behavior
4. Abaxis Launches The VetScan(R) HM5 a State-of-the-Art 5-Part Differential Veterinary Hematology Analyzer
5. Sense of taste different in women with anorexia nervosa
6. Babies raised in bilingual homes learn new words differently than infants learning one language
7. Children would need different medical care in wake of dirty bomb
8. Penn researchers use brain imaging to demonstrate how men and women cope differently under stress
9. Multiple Sclerosis Patients Find Dietary Treatment More Effective Than Pharmaceutical Regimens
10. Liver cancer marker could yield blood test for early detection
11. Improving doctor-patient communication yields significant health benefits
Post Your Comments:
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
Breaking Medicine Technology: